Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...102103104105106107108109110111112...123124»
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New P2 trial, PD(L)-1 Biomarker, Metastases:  Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 28, 2020   
    P2,  N=76, Not yet recruiting, 
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, Journal:  Fournier's gangrene during lenvatinib treatment: A case report. (Pubmed Central) -  Apr 28, 2020   
    The condition was likely due to a perturbation of vascular endothelial cells of the skin due to the inhibition of VEGF/VEGFR signaling. Fournier's gangrene may be a class effect of antiangiogenic treatment that clinicians should be aware of, as early diagnosis and treatment are associated with an improved outcome.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, PD(L)-1 Biomarker:  Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) -  Apr 24, 2020   
    P2,  N=60, Active, not recruiting, 
    Weekends-off administration of lenvatinib was useful to recover the therapeutic response and tolerability toward AEs. Recruiting --> Active, not recruiting
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. (Pubmed Central) -  Apr 17, 2020   
    After nearly a decade with sorafenib as the only approved treatment, multiple new agents have demonstrated efficacy in clinical trials, including the targeted therapies regorafenib, lenvatinib and cabozantinib, the anti-angiogenic antibody ramucirumab, and the immune checkpoint inhibitors nivolumab and pembrolizumab...The release of such data sets to the public enhances the ability to search for information from these legacy studies and provides the opportunity to leverage them to understand HCC mechanisms, rationally develop new therapeutics and identify candidate biomarkers of treatment response. Here, we provide a comprehensive review of public data sets related to HCC and discuss how emerging artificial intelligence methods can be applied to identify new targets and drugs as well as to guide therapeutic choices for improved HCC treatment.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal, IO Biomarker:  Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. (Pubmed Central) -  Apr 16, 2020   
    Furthermore, other mutation-specific drugs, immunotherapies, and novel strategies for advanced thyroid cancer are under investigation. Understanding the molecular basis of thyroid cancer, the drugs of interest for treatment of advanced thyroid cancer, and how these drugs can be administered safely and in the appropriate clinical scenario is the topic of this review.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 15, 2020   
    P1b,  N=30, Active, not recruiting, 
    Recruiting --> Completed | N=40 --> 5 | Trial primary completion date: Apr 2019 --> Oct 2019 Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal, Checkpoint inhibition:  Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. (Pubmed Central) -  Apr 14, 2020   
    Cabozantinib, regorafenib, and ramucirumab also displayed promising results in second line settings...Moreover,nivolumab and pembrolizumab,two therapeutics against the Programmed death (PD)-ligand 1 (PD-L1)/PD1 axis have been recently approvedfor subsequent-line therapy...Therefore, a lot of combinatory approaches are under investigation, including the combination of different immune checkpoint inhibitors (ICIs), the addition of ICIs after resection or during loco-regional therapy, ICIs in addition to kinase inhibitors, anti-angiogenic therapeutics, and others. This review focuses on the use of ICIs for the hepatocellular carcinoma with a careful assessmentof new ICIs-based combinatory approaches.
  • ||||||||||  Caprelsa (vandetanib) / Sanofi, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
    Trial primary completion date, Metastases:  Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (clinicaltrials.gov) -  Apr 9, 2020   
    P2,  N=6, Active, not recruiting, 
    HCC is a potentially lethal malignant tumor and the combination of immunotherapy plus anti-angiogenic inhibitors shows promising outcome for advanced diseases. Trial primary completion date: Dec 2022 --> Dec 2020
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Value of lenvatinib for the treatment of advanced hepatocellular carcinoma (Pubmed Central) -  Apr 9, 2020   
    Lenvatinib can extend the overall survival in a percentage of medium-advanced hepatocellular carcinoma patients who were unresectable and refractory to TACE. Although the incidence of adverse events is high, most of them are mild and reversible.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  ALTER-H-002: Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 3, 2020   
    P2,  N=28, Recruiting, 
    It is unclear whether this response was due to the combination of Gemcitabine-Oxaliplatin-Lenvatinib or Lenvatinib alone. Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Dramatic Clinical Response to Lenvatinib in a Pediatric Patient with Advanced Metastatic Papillary Thyroid Carcinoma (ENDOExpo, Booth 625) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4355;    
    On lenvatinib treatment, our patient showed significant clinical improvement, arrest of disease progression, and stable disease on imaging studies. This case shows that lenvatinib may be a beneficial option for children with advanced PTC not amenable to surgery/RAI treatment and may be used as a bridge to these first-line therapies.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. (Pubmed Central) -  Mar 26, 2020   
    PD0325901, MEK inhibitor, caused the same changes in HCC cells as those described above for lenvatinib and E7090. These results reveal that the FGF signaling pathway through MAPK cascades plays an important role in survival of HCC cell lines with an activated FGF signaling pathway under limited nutrients, and FGFR-MAPK cascades likely contribute to survival of HCC cells with an activated FGF signaling pathway under tumor microenvironments with limited nutrients, where tumor angiogenesis is inhibited.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. (Pubmed Central) -  Mar 25, 2020   
    Regorafenib, cabozantinib, and ramucirumab are appropriate supplements for sorafenib as second-line treatment for patients with advanced HCC who are resistant, show progression or do not tolerate sorafenib...Despite phase III trials for nivolumab and pembrolizumab, the primary endpoints of improved OS were not statistically significant, immune PD-1/PD-L1 checkpoint therapy remains to be further investigated. This review summarizes the development and progression of molecular targeted and immune-based checkpoint therapies in HCC.